033 – ICPT Takes the Lead in NASH

In today’s episode, I breakdown the ICPT NASH results, followed up by a quick take on SAGE and the latest buyout rumors.

*this is not investment advice*

Relevant links:
http://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-positive-topline-results-pivotal-phase-3
https://www.sagerx.com/

http://www.breakingbiotech.com

 

Viking Therapeutics and Madrigal Pharma go head-to-head

Viking Therapeutics reports their latest phase 2 data with their candidate thyroid hormone receptor β agonist. I compare both the madrigal and viking drug and discuss their potential in the NASH/NAFLD space.

 

*This is not investment advice*

 

 

Relevant links:

http://ir.vikingtherapeutics.com/2018-09-18-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol
https://clinicaltrials.gov/ct2/show/NCT02912260?term=madrigal&rank=4
https://clinicaltrials.gov/ct2/show/NCT02927184?term=viking+therapeutics&rank=1

Click to access Madrigal-Company-Overview-September-2018.FINAL_.20180903.pdf

 
%d bloggers like this: